Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA
G. Paolo Rizzardi, … , Adriano Lazzarin, Giuseppe Pantaleo
G. Paolo Rizzardi, … , Adriano Lazzarin, Giuseppe Pantaleo
Published March 15, 2000
Citation Information: J Clin Invest. 2000;105(6):777-782. https://doi.org/10.1172/JCI9079.
View: Text | PDF
Article Article has an altmetric score of 4

Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA

Abstract

Effective therapeutic interventions and clinical care of adults infected with HIV-1 require an understanding of factors that influence time of response to antiretroviral therapy. We have studied a cohort of 118 HIV-1–infected subjects naive to antiretroviral therapy and have correlated the time of response to treatment with a series of virological and immunological measures, including levels of viral load in blood and lymph node, percent of CD4 T cells in lymph nodes, and CD4 T-cell count in blood at study entry. Suppression of viremia below the limit of detection, 50 HIV-1 RNA copies/mL of plasma, served as a benchmark for a successful virological response. We employed these correlations to predict the length of treatment required to attain a virological response in each patient. Baseline plasma viremia emerged as the factor most tightly correlated with the duration of treatment required, allowing us to estimate the required time as a function of this one measure.

Authors

G. Paolo Rizzardi, Rob J. De Boer, Shelley Hoover, Giuseppe Tambussi, Aude Chapuis, Nermin Halkic, Pierre-Alexandre Bart, Veronica Miller, Schlomo Staszewski, Daan W. Notermans, Luc Perrin, Cecil H. Fox, Joep M.A. Lange, Adriano Lazzarin, Giuseppe Pantaleo

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Correlation analyses among virological measures in blood and lymph nodes...
Correlation analyses among virological measures in blood and lymph nodes of 53 HIV-1–infected persons before the initiation of HAART. (a) Correlation between the number of HIV-1–expressing cells in lymph nodes and plasma HIV-1 RNA levels. (b) Correlation between FDC-associated HIV-1 RNA and the number of HIV-1–expressing cells in lymph node. (c) Correlation between FDC-associated HIV-1 RNA and plasma HIV-1 RNA levels. Plasma HIV-1 RNA levels are expressed in log10 copies per milliliter, the number of HIV-1–expressing cells is expressed in lymph node log10 cells per 100 mm2 of lymphoid tissue, and FDC-associated HIV-1 RNA levels in lymph node are expressed in log10 viral genomic equivalents (VGE) per square millimeter of lymphoid tissue; 1 VGE corresponds to 2 HIV-1 RNA copies. The regression lines are shown. Quantitation of plasma viremia and of virological measures in lymph node were performed as described in Methods. A 2-tailed P value < 0.05 was considered significant.